Te­va’s one-time block­buster-to-be — and now re­cur­ring em­bar­rass­ment — laquin­i­mod fails yet again, this time for Hunt­ing­ton’s

Te­va has added yet an­oth­er crit­i­cal fail­ure for laquin­i­mod, which may fi­nal­ly be put on the chop­ping block.

The com­pa­ny’s part­ners at Ac­tive Biotech $AC­TI an­nounced that their Phase II study for Hunt­ing­ton’s dis­ease failed, which comes on top of mul­ti­ple fail­ures in mul­ti­ple scle­ro­sis. Ac­tive’s stock tum­bled 37% on the news of the lat­est mishap.

Once billed as a like­ly block­buster that would one day suc­ceed Co­pax­one, laquin­i­mod racked up ex­pen­sive fail­ures in re­laps­ing, re­mit­ting and pro­gres­sive MS. The Hunt­ing­ton’s Phase II got start­ed 4 years ago. And the tri­al fail­ure wipes out one of the few re­main­ing ef­forts that Te­va had in Phase II/Phase III de­vel­op­ment.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER